$DDXS diaDexus to Present at the Oppenheimer Healt
Post# of 94266
Posted On: 11/20/2013 8:14:30 AM
$DDXS diaDexus to Present at the Oppenheimer Healthcare Conference
diaDexus, Inc. (OTCQB
DXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced that Brian E. Ward, Ph.D., president and chief executive officer, is scheduled to present at the Oppenheimer 24th Annual Healthcare Conference at Crowne Plaza Hotel in New York City. Dr. Ward will provide a corporate overview and update and will be available to conduct one-on-one meetings with investors.
Event:
Oppenheimer 24th Annual Healthcare Conference
Date:
Tuesday, December 10, 2013
Time:
3:55 p.m. Eastern Time
A live webcast of the presentation will be accessible on diaDexus' website at www.diaDexus.com. Please go to the website a few minutes early, as it may be necessary to download audio software to hear the presentation. A replay of the webcast will also be available after the conference concludes.
About diaDexus, Inc.
diaDexus, Inc., based in South San Francisco, California, develops and commercializes proprietary cardiovascular diagnostic products addressing unmet needs in cardiovascular disease. The company's PLAC® Test ELISA Kit is the only blood test cleared by the FDA to aid in predicting risk for both coronary heart disease and ischemic stroke associated with atherosclerosis, the #1 and #3 causes of death, respectively, in the United States. The company's PLAC® Test for Lp-PLA2 Activity, a CE-marked test, is an indicator of atherosclerotic cardiovascular disease, the #1 cause of death in Europe. diaDexus is ISO 13485 certified and manufactures the PLAC Test for Lp-PLA2 Activity on-site. For more information, please visit the company's website at www.diaDexus.com.
diaDexus, Inc.
Brian E. Ward, Ph.D., 650-246-6400
CEO
or
Jean-Frédéric Viret, Ph.D., 650-246-6400
CFO
investors@diadexus.com
or
Media and Investors:
BrewLife
Joey Fleury, 415-946-1090
jfleury@brewlife.com
diaDexus, Inc. (OTCQB
DXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced that Brian E. Ward, Ph.D., president and chief executive officer, is scheduled to present at the Oppenheimer 24th Annual Healthcare Conference at Crowne Plaza Hotel in New York City. Dr. Ward will provide a corporate overview and update and will be available to conduct one-on-one meetings with investors. Event:
Oppenheimer 24th Annual Healthcare Conference
Date:
Tuesday, December 10, 2013
Time:
3:55 p.m. Eastern Time
A live webcast of the presentation will be accessible on diaDexus' website at www.diaDexus.com. Please go to the website a few minutes early, as it may be necessary to download audio software to hear the presentation. A replay of the webcast will also be available after the conference concludes.
About diaDexus, Inc.
diaDexus, Inc., based in South San Francisco, California, develops and commercializes proprietary cardiovascular diagnostic products addressing unmet needs in cardiovascular disease. The company's PLAC® Test ELISA Kit is the only blood test cleared by the FDA to aid in predicting risk for both coronary heart disease and ischemic stroke associated with atherosclerosis, the #1 and #3 causes of death, respectively, in the United States. The company's PLAC® Test for Lp-PLA2 Activity, a CE-marked test, is an indicator of atherosclerotic cardiovascular disease, the #1 cause of death in Europe. diaDexus is ISO 13485 certified and manufactures the PLAC Test for Lp-PLA2 Activity on-site. For more information, please visit the company's website at www.diaDexus.com.
diaDexus, Inc.
Brian E. Ward, Ph.D., 650-246-6400
CEO
or
Jean-Frédéric Viret, Ph.D., 650-246-6400
CFO
investors@diadexus.com
or
Media and Investors:
BrewLife
Joey Fleury, 415-946-1090
jfleury@brewlife.com
(0)
(0)